Måndag 20 April | 13:16:14 Europe / Stockholm

Kalender

Est. tid*
2026-10-20 08:35 Kvartalsrapport 2026-Q3
2026-07-09 08:35 Kvartalsrapport 2026-Q2
2026-05-06 N/A X-dag ordinarie utdelning GENT 0.60 NOK
2026-05-06 08:35 Kvartalsrapport 2026-Q1
2026-05-05 N/A Årsstämma
2026-02-11 - Bokslutskommuniké 2025
2025-10-23 - Kvartalsrapport 2025-Q3
2025-07-10 - Kvartalsrapport 2025-Q2
2025-05-07 - X-dag ordinarie utdelning GENT 0.40 NOK
2025-05-07 - Kvartalsrapport 2025-Q1
2025-05-06 - Årsstämma
2025-02-12 - Bokslutskommuniké 2024
2024-10-31 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-04-30 - X-dag ordinarie utdelning GENT 0.00 NOK
2024-04-30 - Kvartalsrapport 2024-Q1
2024-04-29 - Årsstämma
2024-02-09 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-08-24 - Kvartalsrapport 2023-Q2
2023-05-05 - X-dag ordinarie utdelning GENT 0.00 NOK
2023-05-05 - Kvartalsrapport 2023-Q1
2023-05-04 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning GENT 0.00 NOK
2022-05-18 - Årsstämma
2022-04-28 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-10-21 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-05 - X-dag ordinarie utdelning GENT 0.00 NOK
2021-05-04 - Årsstämma
2021-04-16 - Kvartalsrapport 2021-Q1
2021-02-11 - Bokslutskommuniké 2020
2020-10-29 - Kvartalsrapport 2020-Q3
2020-08-21 - Kvartalsrapport 2020-Q2
2020-05-15 - X-dag ordinarie utdelning GENT 0.00 NOK
2020-05-14 - Årsstämma
2020-04-24 - Kvartalsrapport 2020-Q1
2020-02-14 - Bokslutskommuniké 2019
2019-11-21 - Extra Bolagsstämma 2019
2019-05-10 - X-dag ordinarie utdelning GENT 0.00 NOK
2018-07-13 - Extra Bolagsstämma 2018
2018-06-13 - X-dag ordinarie utdelning GENT 0.00 NOK
2018-02-27 - Bokslutskommuniké 2017
2017-06-06 - Årsstämma

Beskrivning

LandNorge
ListaOslo Bors
SektorHälsovård
IndustriMedicinteknik
Gentian Diagnostics är ett medicinskt diagnostikbolag som utvecklar och tillverkar in vitro diagnostiska reagenser för högkapacitetsanalysatorer. Gentians expertis och fokus ligger inom homogena immunanalyser, speciellt infektioner, inflammationer, njursvikt och kongestiv hjärtsvikt. Bolagets huvudkontor och produktionsanläggningar finns i Moss, Norge, och betjänar den globala human- och veterinärdiagnostikmarknaden genom försäljnings- och representationskontor i ett antal nyckelländer.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-04-20 11:04:49
Moss, 20 April 2026

Gentian Diagnostics, a fast-growing developer and manufacturer of high-quality
diagnostic assays, is pleased to announce the renewal of its long-term supply
agreement with Bühlmann Laboratories for faecal calprotectin. Under the renewed
agreement, Gentian will continue to supply key materials for Bühlmann
Laboratories market-leading faecal calprotectin assay, fCAL Turbo®.

The renewal underscores the strength of the long standing collaboration between
Gentian and Bühlmann Laboratories and reflects a shared commitment to advancing
faecal calprotectin testing to support improved diagnosis and monitoring of
inflammatory bowel disease.

Matti Heinonen, CEO of Gentian Diagnostics ASA, commented: "We are very pleased
to extend our partnership with Bühlmann Laboratories. Bühlmann has proven to be
a strong partner with a continued commitment to developing the faecal
calprotectin market. This agreement provides a solid foundation for long term
value creation for both companies."

Christian Eberle, CEO of Bühlmann Laboratories AG, stated: "This new agreement
with our long standing partner Gentian ensures continuity and provides a strong
foundation for our collaboration going forward."

For further information, please contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT) develops and manufactures high-quality in vitro
diagnostic reagents. Our mission is to improve diagnostic efficiency to support
better treatment decisions. Gentian's expertise and focus lie in immunoassays,
specifically within infections, inflammation, kidney disease, and heart failure.
By converting existing, clinically relevant biomarkers to the most efficient
high throughput analysers, the company contributes to cost savings and helps
protect lives. Gentian Diagnostics is headquartered in Moss, Norway, and serves
the global human and veterinary diagnostics markets through sales and
representative offices in Sweden, the USA, and China. For more information,
please visit www.gentian.com.